Specialty medical injectable drug program, requirements and drug policy updates

New specialty medical injectable updates and requirements announced.

June 27, 2023

Review the following tables to determine changes to our specialty medical injectable drug programs.

SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH

Drug Name

UnitedHealthcare Commercial

Treatment Uses

Elfabrio®

(pegunigalsidase alfa-iwxj)

X

For the treatment of adults with Fabry disease.

Qalsody^TM

(tofersen)

X

For the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.

For questions, please contact your broker or UnitedHealthcare representative.

Current broker or employer group client?

Access uhceservices to check commissions, manage eligibility, request ID cards and more.

Sign in

Specialty medical injectable drug program, requirements and drug policy updates

More articles

Broker - Page template - More news Experience Fragment

Current broker or employer group client?